Cargando…

O1.7. PROTEOMIC ANALYSIS OF BLOOD BASED SAMPLES FROM THE OPTiMiSE (OPTIMIZATION OF TREATMENT AND MANAGEMENT OF SCHIZOPHRENIA IN EUROPE) STUDY POINT TOWARDS COMPLEMENT PATHWAY PROTEIN CHANGES

BACKGROUND: The OPTiMiSE (Optimization of Treatment and Management of Schizophrenia in Europe) trial may help in the identification of predictors of treatment response. Medication naïve patients with first episode schizophrenia or schizophreniform disorder were enrolled in the study and treated open...

Descripción completa

Detalles Bibliográficos
Autores principales:	Föcking, Melanie, Pollak, Thomas, Dicker, Patrick, Cagney, Gerard, Winter, Inge, Kahn, Rene, McGuire, Philip, Cotter, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888760/ http://dx.doi.org/10.1093/schbul/sby015.189

Ejemplares similares

Association of Complement and Coagulation Pathway Proteins With Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial
por: Susai, Subash Raj, et al.
Publicado: (2023)

Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study
por: Demjaha, Arsime, et al.
Publicado: (2023)

Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study
por: Martinuzzi, Emanuela, et al.
Publicado: (2019)

Correction: Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study
por: Martinuzzi, Emanuela, et al.
Publicado: (2019)

Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis
por: Heurich, Meike, et al.
Publicado: (2021)

Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies
por: Worker, Amanda, et al.
Publicado: (2023)

Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort)
por: Pandit, R., et al.
Publicado: (2019)

Reduced protein synthesis in schizophrenia patient-derived olfactory cells
por: English, J A, et al.
Publicado: (2015)

Peripheral complement proteins in schizophrenia: A systematic review and meta-analysis of serological studies
por: Mongan, David, et al.
Publicado: (2020)

Complement pathway changes at age 12 are associated with psychotic experiences at age 18 in a longitudinal population-based study: evidence for a role of stress
por: Föcking, Melanie, et al.
Publicado: (2019)

31.1 OPTIMISING THE TREATMENT AND MANAGEMENT OF FIRST-EPISODE SCHIZOPHRENIA: THE OPTIMISE CLINICAL TRIAL
por: Kahn, René
Publicado: (2018)

A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort)
por: ter Hark, Sophie E, et al.
Publicado: (2020)

Proteomic analysis of the postsynaptic density implicates synaptic function and energy pathways in bipolar disorder
por: Föcking, M, et al.
Publicado: (2016)

Searching for bridges between psychopathology and real-world functioning in first-episode psychosis: A network analysis from the OPTiMiSE trial
por: Dal Santo, Francesco, et al.
Publicado: (2022)

Searching for bridges between psychopathology and real-world functioning in first-episode psychosis: a network analysis from the OPTiMiSE trial
por: Dal Santo, F., et al.
Publicado: (2023)

OPtimising Treatment for MIld Systolic hypertension in the Elderly (OPTiMISE): protocol for a randomised controlled non-inferiority trial
por: Sheppard, James P, et al.
Publicado: (2018)

Omega-3 fatty acid deficiency disrupts endocytosis, neuritogenesis, and mitochondrial protein pathways in the mouse hippocampus
por: English, Jane A., et al.
Publicado: (2013)

Dataset of mouse hippocampus profiled by LC–MS/MS for label-free quantitation
por: English, Jane A., et al.
Publicado: (2016)

Cost-Effectiveness of Antihypertensive Deprescribing in Primary Care: a Markov Modelling Study Using Data From the OPTiMISE Trial
por: Jowett, Sue, et al.
Publicado: (2022)

Blood-Based Protein Changes in Childhood Are Associated With Increased Risk for Later Psychotic Disorder: Evidence From a Nested Case–Control Study of the ALSPAC Longitudinal Birth Cohort
por: English, Jane A, et al.
Publicado: (2018)

Implementation of an innovative web base support system (Psynary) and Nurse Practitioner led service to support optimisation of treatment for depression (OptiMA2)
por: Kabaila, R., et al.
Publicado: (2022)

Blood Pressure Changes Following Antihypertensive Medication Reduction, by Drug Class and Dose Chosen for Withdrawal: Exploratory Analysis of Data From the OPTiMISE Trial
por: Sheppard, James P., et al.
Publicado: (2021)

Deprescribing to optimise health outcomes for frail older people: a double-blind placebo-controlled randomised controlled trial—outcomes of the Opti-med study
por: Etherton-Beer, Christopher, et al.
Publicado: (2023)

Optimized Brain Extraction for Pathological Brains (optiBET)
por: Lutkenhoff, Evan S., et al.
Publicado: (2014)

OptiPrep Density Gradient Solutions for Nonmammalian Organelles
por: Graham, John M.
Publicado: (2002)

OptiPrep™ Density Gradient Solutions for Mammalian Organelles
por: Graham, John
Publicado: (2002)

OptiPharm: An evolutionary algorithm to compare shape similarity
por: Puertas-Martín, S., et al.
Publicado: (2019)

32.4 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18
por: Cotter, David, et al.
Publicado: (2018)

Opti-Med: the effectiveness of optimised clinical medication reviews in older people with ‘geriatric giants’ in general practice; study protocol of a cluster randomised controlled trial
por: Willeboordse, Floor, et al.
Publicado: (2014)

O1.1 ALTERED COMPLEMENT PATHWAY PROTEIN EXPRESSION IS ASSOCIATED WITH PSYCHOTIC EXPERIENCES AT AGE 11 WHICH PERSIST AT AGE 18
por: Cotter, David, et al.
Publicado: (2018)

Performance of the OptiMAL(®) dipstick in the diagnosis of malaria infection in pregnancy
por: Tagbor, Harry, et al.
Publicado: (2008)

OptiPrep? Density Gradient Solutions for Macromolecules and Macromolecular Complexes
por: Graham, John
Publicado: (2002)

New approach to simplifying and optimising acute malnutrition treatment in children aged 6–59 months: the OptiMA single-arm proof-of-concept trial in Burkina Faso
por: Daures, Maguy, et al.
Publicado: (2020)

17.1 A RANDOMIZED CONTROLLED TRIAL OF CANNABIDIOL IN SCHIZOPHRENIA
por: McGuire, Philip, et al.
Publicado: (2018)

Attenuation artifacts in light sheet fluorescence microscopy corrected by OPTiSPIM
por: Mayer, Jürgen, et al.
Publicado: (2018)

OptiFit: an Improved Method for Fitting Amplicon Sequences to Existing OTUs
por: Sovacool, Kelly L., et al.
Publicado: (2022)

Schizophrenia: Complement Cleaning or Killing
por: Hogenaar, Jirrine T.T., et al.
Publicado: (2021)

Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder?
por: Föcking, Melanie, et al.
Publicado: (2016)

Stepped wedge cluster randomised controlled trial to assess the effectiveness of an optimisation strategy for general anaesthesia on postoperative morbidity and mortality in elderly patients (the OPTI-AGED study): a study protocol
por: Molliex, Serge, et al.
Publicado: (2018)

OptiType: precision HLA typing from next-generation sequencing data
por: Szolek, András, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_inu4gk59amsfot7gnq864ukief